| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMOA1714631 |
| P698 | PubMed publication ID | 29768152 |
| P50 | author | Orrin Devinsky | Q7104080 |
| P2093 | author name string | J Helen Cross | |
| Elaine C Wirrell | |||
| Sameer M Zuberi | |||
| Claire Roberts | |||
| Michael Privitera | |||
| Vicente Villanueva | |||
| Anup D Patel | |||
| Daniel Checketts | |||
| Sam M Greenwood | |||
| Kevan E VanLandingham | |||
| GWPCARE3 Study Group | |||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabidiol | Q422917 |
| P304 | page(s) | 1888-1897 | |
| P577 | publication date | 2018-05-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome | |
| P478 | volume | 378 |
| Q90534059 | "Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents |
| Q92676487 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment |
| Q91805689 | A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects |
| Q58094316 | A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects |
| Q98771374 | A Survey on Cannabinoid Treatment of Pediatric Epilepsy Among Neuropediatricians in Scandinavia and Germany |
| Q59808748 | A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans |
| Q89506050 | A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects |
| Q67223781 | A systematic review of cannabidiol dosing in clinical populations |
| Q89611766 | Abrupt withdrawal of cannabidiol (CBD): A randomized trial |
| Q57054788 | Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial |
| Q99351957 | Add-on cannabidiol significantly decreases seizures in 3 patients with SYNGAP1 developmental and epileptic encephalopathy |
| Q91731937 | Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials |
| Q92282664 | Antioxidative and Anti-Inflammatory Properties of Cannabidiol |
| Q58088545 | Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study |
| Q91628572 | Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study |
| Q92093035 | CBD: A New Hope? |
| Q92509980 | Cannabidiol Adverse Effects and Toxicity |
| Q100458340 | Cannabidiol and Abnormal Liver Chemistries in Healthy Adults: Results of a Phase 1 Clinical Trial |
| Q97428443 | Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research |
| Q90020725 | Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice |
| Q62673654 | Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study |
| Q90313291 | Cannabidiol in treatment of refractory epileptic spasms: An open-label study |
| Q89531275 | Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand |
| Q92803709 | Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus |
| Q57148532 | Cannabinoid Delivery Systems for Pain and Inflammation Treatment |
| Q89907362 | Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects |
| Q64108597 | Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination |
| Q57159308 | Cannabis for the Treatment of Epilepsy: an Update |
| Q90004086 | Cannabis treatment in children with epilepsy: Practices of Canadian neurologists |
| Q91897310 | Cannabis-based medicines and the perioperative physician |
| Q103025704 | Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy |
| Q98218022 | Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy |
| Q64974261 | Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. |
| Q57468371 | Current Treatment Strategies and Future Treatment Options for Dravet Syndrome |
| Q89970840 | Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial |
| Q88955693 | Drop seizures cut by cannabidiol |
| Q98772110 | Drug-Drug Interactions Between Cannabidiol and Lithium |
| Q90099305 | Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures |
| Q92419716 | Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program |
| Q98882462 | Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy |
| Q58613951 | Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis |
| Q92537399 | Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy |
| Q91297514 | Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis |
| Q92382246 | Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers |
| Q64087352 | Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects |
| Q91241221 | Epilepsy in adults |
| Q91752161 | Evolution and course of early life developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome |
| Q97522306 | Expectations and knowledge of cannabidiol therapy for childhood epilepsy - A German caregiver survey |
| Q91991227 | Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment |
| Q64930642 | Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model. |
| Q91708013 | Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol |
| Q91725282 | Highlights From the Annual Meeting of the American Epilepsy Society 2018 |
| Q91856722 | Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort |
| Q92663233 | Knowledge, expectations and fears of cannabis use of epilepsy patients at a tertiary epilepsy center |
| Q99711797 | Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products |
| Q102050618 | Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program |
| Q61806317 | Lower circulating endocannabinoid levels in children with autism spectrum disorder |
| Q102998051 | Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review |
| Q93106408 | Marijuana use among patients with epilepsy at a tertiary care center |
| Q89526804 | Medical Cannabis for Intractable Epilepsy in Childhood: A Review |
| Q89526807 | Medical Cannabis in Children |
| Q93036841 | New Targeted Treatments for Fragile X Syndrome |
| Q98218002 | Nonseizure consequences of Dravet syndrome, KCNQ2-DEE, KCNB1-DEE, Lennox-Gastaut syndrome, ESES: A functional framework |
| Q93167550 | Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects |
| Q61813934 | Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation |
| Q92855818 | Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration |
| Q91759988 | Parasitic pharmacology: A plausible mechanism of action for cannabidiol |
| Q91721752 | Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy |
| Q92989549 | Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada |
| Q98779243 | Potential Pharmacokinetic Drug-Drug Interactions between Cannabinoids and Drugs Used for Chronic Pain |
| Q91578309 | Priming primary care providers to engage in evidence-based discussions about cannabis with patients |
| Q90319280 | Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa |
| Q90018102 | Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy |
| Q97646628 | Report of a 6-month-old Asian infant with early infantile epileptic encephalopathy whose seizures were eliminated by cannabidiol |
| Q64274255 | Role of the Angiotensin Pathway and its Target Therapy in Epilepsy Management |
| Q92610796 | Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders |
| Q99237714 | Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study |
| Q91804466 | Synthetic pharmaceutical grade cannabidiol for treatment of refractory infantile spasms: A multicenter phase-2 study |
| Q98507441 | The Essential Medicinal Chemistry of Cannabidiol (CBD) |
| Q91762308 | The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids |
| Q90069383 | The complexity of pharmacology of cannabidiol (CBD) and its implications in the treatment of brain disorders |
| Q98165843 | The effect of cannabidiol on simulated car driving performance: A randomised, double-blind, placebo-controlled, crossover, dose-ranging clinical trial protocol |
| Q64110707 | The endocannabinoid system and stroke: A focused review |
| Q92878674 | The nephrologist's guide to cannabis and cannabinoids |
| Q57811188 | The neuropsychopharmacology of cannabis: a review of human imaging studies |
| Q57300019 | Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age |
| Q90621066 | Treatment of epilepsy in light of the most recent advances |
| Q90625641 | Treatment of infantile spasms |
| Q64250628 | Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials |
| Q96680296 | Use of cannabis and its products among patients in a tertiary epilepsy center: A cross-sectional survey |
| Q92297582 | fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy |
Search more.